This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down
by Zacks Equity Research
Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.
McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.
Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.
Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.
Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth
by Zacks Equity Research
Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).
HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Healthy Top-Line Growth Buoy Jabil (JBL) Q1 Earnings?
by Zacks Equity Research
Backed by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics, Jabil (JBL) is likely to record healthy fiscal first-quarter revenues.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Neogen (NEOG) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Launches Test for Detection of Cashew Allergen
by Zacks Equity Research
Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).
Neogen (NEOG) Finalizes Food Safety Business Merger With 3M
by Zacks Equity Research
The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.
Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
by Zacks Equity Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.